Clinical Trial Update: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation [Phase 1]

View source ↗

Summary

NT-175 is being studied in a Phase 1 trial enrolling adults with unresectable, advanced, or metastatic solid tumors positive for HLA-A*02:01 and TP53 R175H muta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Adenocarcinoma

Drugs mentioned

• NT-175

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: RECRUITING